Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

(2017) Jun Ishihara et al.   Science Translational Medicine

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists

(2017) Frédéric Illouz et al.   Cancer Medicine

Influence of immunoglobulin isotype on therapeutic antibody function

(2016) Stephen A. Beers et al.   BLOOD

Management of toxicities of immune checkpoint inhibitors

(2016) Lavinia Spain et al.   CANCER TREATMENT REVIEWS

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood

(2016) Katrin Klocke et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

(2015) Rony Dahan et al.   CANCER CELL

Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer

(2015) N. Gul et al.   CANCER RESEARCH

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients

(2014) E. Cha et al.   Science Translational Medicine

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo

(2014) Linda C Sandin et al.   OncoImmunology

Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma

(2013) Igor Z. Barjaktarevic et al.   CHEST

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ipilimumab and Its Toxicities: A Multidisciplinary Approach

(2013) L. A. Fecher et al.   ONCOLOGIST

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Basis of CTLA-4 function in regulatory and conventional CD4+ T cells

(2012) X. Tai et al.   BLOOD

Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma

(2012) David E. Kleiner et al.   DIGESTIVE DISEASES AND SCIENCES

Mouse model recapitulating human Fc  receptor structural and functional diversity

(2012) P. Smith et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Taming tissue-specific T cells: CTLA-4 reins in self-reactive T cells

(2010) Alison M Paterson et al.   NATURE IMMUNOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

(2010) M. A. Curran et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CTLA-4 suppresses the pathogenicity of self antigen–specific T cells by cell-intrinsic and cell-extrinsic mechanisms

(2009) Wataru Ise et al.   NATURE IMMUNOLOGY

T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade

(2008) Dmitry V. Ostanin et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

(2008) B. Kavanagh et al.   BLOOD

The Foxp3+ regulatory T cell: a jack of all trades, master of regulation

(2008) Qizhi Tang et al.   NATURE IMMUNOLOGY

SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade

(2008) M. Fasso et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA